Illumina, Inc. (ILMN)
NASDAQ: ILMN · Real-Time Price · USD
94.79
+0.63 (0.67%)
At close: Jun 27, 2025, 4:00 PM
94.75
-0.04 (-0.04%)
After-hours: Jun 27, 2025, 7:00 PM EDT
Illumina Revenue
Illumina had revenue of $1.04B in the quarter ending March 30, 2025, a decrease of -3.25%. This brings the company's revenue in the last twelve months to $4.34B, down -3.47% year-over-year. In the year 2024, Illumina had annual revenue of $4.37B, down -2.93%.
Revenue (ttm)
$4.34B
Revenue Growth
-3.47%
P/S Ratio
3.48
Revenue / Employee
$418,226
Employees
10,370
Market Cap
15.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 4.37B | -132.00M | -2.93% |
| Dec 31, 2023 | 4.50B | -80.00M | -1.75% |
| Jan 1, 2023 | 4.58B | 58.00M | 1.28% |
| Jan 2, 2022 | 4.53B | 1.29B | 39.73% |
| Jan 3, 2021 | 3.24B | -304.00M | -8.58% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
ILMN News
- 5 days ago - Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy - PRNewsWire
- 10 days ago - Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling - Business Wire
- 18 days ago - lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics - PRNewsWire
- 4 weeks ago - Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis - PRNewsWire
- 4 weeks ago - Illumina, Inc. (ILMN) Bernstein 41st Annual Strategic Decisions Conference (Transcript) - Seeking Alpha
- 4 weeks ago - Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies - PRNewsWire
- 5 weeks ago - Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel - Business Wire
- 6 weeks ago - Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90% - Benzinga